The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Subscribe To Our Newsletter & Stay Updated
